共 36 条
- [1] Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Clinical Drug Investigation, 2023, 43 : 595 - 603
- [3] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (09): : 1000 - 1010
- [5] Urine and Plasma Complement Ba Levels During Disease Flares in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2421 - 2427
- [7] Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis ARTHRITIS AND RHEUMATISM, 2013, 65 : S1191 - S1192
- [8] Circulating level of high mobility group box-1 is associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis PRESSE MEDICALE, 2013, 42 (04): : 757 - 758